http://dailynews.yahoo.com/h/nm/20011218/hl/allergies_1.html
Tuesday December 18 5:54 PM ET
By Suzanne Rostler
NEW YORK (Reuters Health) - Results of a new study may provide hope to some of
the millions who endure the itchy eyes, runny nose and incessant sneezing
associated with seasonal allergies.
According to the report, an experimental vaccine can block allergy-causing
compounds released in response to a trigger such as pollen, from causing a
range of uncomfortable symptoms. In the US, the costs associated with these
symptoms are estimated at $6 billion a year.
The vaccine, known as omalizumab, is a monoclonal antibody--a
laboratory-manufactured molecule--that binds to IgE, a natural antibody found
in blood that is key in setting off seasonal nasal allergies.
In a study of more than 500 patients from across the US, the vaccine
inhibited IgE and reduced itchy, runny or stuffy nose, watery or red eyes, and
sneezing during ragweed season, compared with an inactive compound (placebo).
As a result, allergy sufferers used fewer antihistamines to control their
symptoms, missed fewer days of work or school, and were better able to get
through their daily activities, report researchers in the December 19th issue
of the Journal of the American Medical Association (news
- web
sites).
The drug's effects on quality of life rose in tandem with the dose, they
note.
``(This is the) first demonstration that lowing IgE, the major antibody
responsible for allergic reactions, is associated with a dose-related
improvement in symptoms, use of rescue medications, and quality of life,'' Dr.
Tomas B. Casale, from Creighton University in Omaha, Nebraska, told Reuters
Health.
He said that while the study included only patients with allergies to
ragweed, the findings should apply to individuals with other allergies.
``Reducing IgE would make one less likely to respond to an allergen no
matter what it is,'' explained Casale, the study's lead author.
But before omalizumab becomes available at the doctor's office, more
research will be needed into possible short- and long-term side effects, costs,
and its effects compared with those of currently-available therapies, notes Dr.
Marshall Plaut of the National Institute of Allergy and Infectious Diseases (news
- web
sites) in Bethesda, Maryland.
Nonetheless, the vaccine is the first of several new, immune-system
targeting agents that ``may change the face of allergy and asthma therapy,'' he
writes in an accompanying editorial.
The study included 536 people ages 12 to 75 with a history of hay fever
brought on by ragweed, one of the more common causes of allergies in the US.
Patients received omalizumab injections at various doses or a placebo three or
four times over 12 weeks. Treatment started just prior to ragweed season.
Several researchers on the study have received funding from or work for
Novartis Pharmaceuticals or Genetech Inc., which are collaborating on
developing omalizumab. The companies funded the study.
SOURCE: Journal of the American Medical Association 2001;286:2956-2967.
Email
this story - View
most popular | Printer-friendly
format
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.